Sector footprint
$432.8M in exports
Reported chemicals exports in 2024 across 33 qualifying HS6 products.
Sector export playbook ยท HS 28-38
Explore Belarus's HS 28-38 product portfolio, buyer markets, growth signals, and diversification opportunities. Use this guide to prioritize research, not to treat calculated indicators as guaranteed sales.
Chemicals capability
Compare exporter scale with product breadth, buyer demand, growth, and destination reach. A large sector does not remove the need for product, compliance, pricing, and buyer validation.
Sector footprint
Reported chemicals exports in 2024 across 33 qualifying HS6 products.
Global demand
The sector's reported buyer import base provides context for product and market prioritization.
How to use the guide
Start with products that combine demand and exporter capability, then validate standards, route economics, buyers, and competition.
Product portfolio
Each HS6 product is ranked by calculated opportunity and shown with reported market size, exporter exports, growth, and destination reach.
| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
|---|---|---|---|---|---|---|
| HS 300490Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $305.0B | $139.4M | $114.7B | +4.5% | 21 | +0.1% |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | $29.2B | $9.0M | $19.7B | +19.6% | 13 | +0.1% |
| HS 293399Heterocyclic compounds: n.e.c. in headings no. 2933 | $9.3B | $11.6K | $11.3B | +51.0% | 2 | +0.0% |
| HS 382200Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $19.8B | $90.3K | $9.1B | +6.6% | 6 | +0.0% |
| HS 300215Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $22.1B | $493.7K | $8.5B | +1.4% | 3 | +0.0% |
| HS 293499Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $12.8B | $32.8K | $8.3B | +8.5% | 3 | +0.0% |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.5B | $47.5K | $7.7B | +25.7% | 4 | +0.0% |
| HS 300214Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $6.6B | $338.6 | $6.2B | -24.2% | 2 | +0.0% |
| HS 330300Perfumes and toilet waters | $8.5B | $168.4K | $5.0B | -1.2% | 3 | +0.0% |
| HS 293379Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $2.2K | $4.8B | +13.1% | 1 | +0.0% |
| HS 310420Fertilizers, mineral or chemical: potassic, potassium chloride | $6.8B | $265.0M | $4.6B | +6.9% | 2 | +3.7% |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $9.3B | $316.4 | $4.4B | +17.4% | 2 | +0.0% |
| HS 381800Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $7.9B | $78.4K | $4.1B | +2.8% | 3 | +0.0% |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $5.8B | $13.8K | $3.6B | +15.9% | 2 | +0.0% |
| HS 382600Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $3.9B | $17.7K | $3.4B | -0.9% | 2 | +0.0% |
| HS 293359Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $3.5B | $2.7K | $3.2B | -15.1% | 1 | +0.0% |
| HS 300420Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $24.4 | $2.0B | -11.3% | 1 | +0.0% |
| HS 293299Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $163.7 | $2.0B | -15.2% | 1 | +0.0% |
| HS 382319Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $54.1K | $1.9B | +81.6% | 1 | +0.0% |
| HS 310540Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $622.5K | $1.8B | +9.3% | 1 | +0.4% |
| HS 380893Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $402.7K | $1.7B | +1.4% | 1 | +0.0% |
| HS 300670Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $1.3 | $1.4B | -4.9% | 1 | +0.0% |
| HS 340220Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $12.1 | $1.4B | -14.5% | 1 | +0.0% |
| HS 310221Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $6.6M | $1.2B | +15.5% | 1 | +2.1% |
| HS 281820Aluminium oxide: other than artificial corundum | $2.3B | $2.1K | $1.1B | +1.5% | 1 | +0.0% |
| HS 284410Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $12.4K | $1.1B | +12.7% | 1 | +0.0% |
| HS 310210Fertilizers, mineral or chemical: nitrogenous, urea, whether or not in aqueous solution | $2.0B | $10.7M | $1.0B | +49.0% | 1 | +0.4% |
| HS 300220Vaccines: for human medicine | $1.5B | $99.4 | $1.0B | -28.6% | 1 | +0.0% |
| HS 294190Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $27.6K | $990.0M | +63.3% | 1 | +0.0% |
| HS 300390Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $2.0B | $23.2 | $981.1M | -18.4% | 1 | +0.0% |
| HS 280461Silicon: containing by weight not less than 99.99% of silicon | $839.5M | $7.5 | $927.8M | -38.9% | 1 | +0.0% |
| HS 293339Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $1.6B | $1.1 | $871.2M | -38.5% | 1 | +0.0% |
| HS 300449Medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts: for therapeutic or prophylactic uses, packaged for retail sale | $1.5B | $788.8 | $841.5M | +10.6% | 1 | +0.0% |
Best markets
Markets are ranked by calculated opportunity across the qualifying products in this sector view.
USA
11 products represented in the sector.
$41.6B$120.0B reported buyer importsDEU
12 products represented in the sector.
$30.6B$65.1B reported buyer importsCHE
1 products represented in the sector.
$27.7B$41.0B reported buyer importsSVN
2 products represented in the sector.
$20.3B$16.2B reported buyer importsNLD
6 products represented in the sector.
$18.9B$32.3B reported buyer importsCHN
7 products represented in the sector.
$17.7B$39.3B reported buyer importsITA
3 products represented in the sector.
$8.4B$23.3B reported buyer importsCAN
5 products represented in the sector.
$8.3B$12.7B reported buyer importsBEL
2 products represented in the sector.
$7.9B$20.3B reported buyer importsESP
3 products represented in the sector.
$7.4B$14.8B reported buyer importsBRA
4 products represented in the sector.
$6.3B$9.3B reported buyer importsGBR
2 products represented in the sector.
$6.1B$16.6B reported buyer importsGrowth stars
Average product-level CAGR is a screening signal. Confirm the latest trend, base effects, buyer quality, and commercial feasibility before acting.
| Product | Average CAGR | Opportunity | Markets |
|---|---|---|---|
| HS 382319Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | +81.6% | $1.9B | 1 |
| HS 294190Antibiotics: n.e.c. in heading no. 2941 | +63.3% | $990.0M | 1 |
| HS 293399Heterocyclic compounds: n.e.c. in headings no. 2933 | +51.0% | $11.3B | 2 |
| HS 310210Fertilizers, mineral or chemical: nitrogenous, urea, whether or not in aqueous solution | +49.0% | $1.0B | 1 |
| HS 330499Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | +25.7% | $7.7B | 4 |
| HS 382499Chemical products, mixtures and preparations: n.e.c. heading 3824 | +19.6% | $19.7B | 13 |
| HS 300212Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | +17.4% | $4.4B | 2 |
| HS 300439Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | +15.9% | $3.6B | 2 |
| HS 310221Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | +15.5% | $1.2B | 1 |
| HS 293379Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | +13.1% | $4.8B | 1 |
Diversification opportunities
Destination count is a simple breadth indicator. It does not measure destination concentration or guarantee resilience.
HS 300490
HS 382499
HS 382200
HS 330499
HS 300215
HS 293499
HS 330300
HS 381800
Frequently asked questions
Practical guidance for interpreting sector scale, growth, product breadth, and buyer markets.
Compare sector exports, product breadth, buyer markets, growth, and global demand. These signals identify research priorities rather than guarantee market access.
Products with higher average reported growth in the screened rows. Validate the time period, base effects, buyer demand, and current exporter position.
Products reaching more buyer markets in the screened data. Destination breadth is useful context but does not replace concentration, route, or buyer analysis.
Data source
OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). OECD BIMTS is the primary trade series for this view. Supporting bilateral trade context uses CEPII BACI bilateral trade flows (202601) under Etalab 2.0 Open Licence. Yugalinks presents derived views of reported observations and calculated indicators. Data terms: OECD Terms & Conditions.